Literature DB >> 20735016

Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ.

Yongjun Wang, Naresh Kumar, Philippe Nuhant, Michael D Cameron, Monica A Istrate, William R Roush, Patrick R Griffin, Thomas P Burris.   

Abstract

The retinoic acid receptor-related receptors (RORs) are members of the nuclear receptor (NR) superfamily of transcription factors. Several NRs are still characterized as orphan receptors because ligands have not yet been identified for these proteins. Here, we describe the identification of a synthetic RORα/RORγ ligand, SR1078. SR1078 modulates the conformation of RORγ in a biochemical assay and activates RORα and RORγ driven transcription. Furthermore, SR1078 stimulates expression of endogenous ROR target genes in HepG2 cells that express both RORα and RORγ. Pharmacokinetic studies indicate that SR1078 displays reasonable exposure following injection into mice, and consistent with SR1078 functioning as a RORα/RORγ agonist, expression of two ROR target genes, glucose-6-phosphatase and fibroblast growth factor 21, were stimulated in the liver. Thus, we have identified the first synthetic RORα/γ agonist, and this compound can be utilized as a chemical tool to probe the function of these receptors both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735016      PMCID: PMC3003750          DOI: 10.1021/cb100223d

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  21 in total

1.  X-ray structure of the hRORalpha LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha.

Authors:  Joerg A Kallen; Jean-Marc Schlaeppi; Francis Bitsch; Sabine Geisse; Martin Geiser; Isabelle Delhon; Brigitte Fournier
Journal:  Structure       Date:  2002-12       Impact factor: 5.006

2.  Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways.

Authors:  Lei Yin; Nan Wu; Joshua C Curtin; Mohammed Qatanani; Nava R Szwergold; Robert A Reid; Gregory M Waitt; Derek J Parks; Kenneth H Pearce; G Bruce Wisely; Mitchell A Lazar
Journal:  Science       Date:  2007-11-15       Impact factor: 47.728

3.  In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism.

Authors:  T Meyer; M Kneissel; J Mariani; B Fournier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

5.  Crystal structure of the human RORalpha Ligand binding domain in complex with cholesterol sulfate at 2.2 A.

Authors:  Joerg Kallen; Jean-Marc Schlaeppi; Francis Bitsch; Isabelle Delhon; Brigitte Fournier
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

6.  A natural product ligand of the oxysterol receptor, liver X receptor.

Authors:  Kelli S Bramlett; Keith A Houck; Kristen M Borchert; Michele S Dowless; Palaniappan Kulanthaivel; Youyan Zhang; Thomas P Beyer; Robert Schmidt; Jeffrey S Thomas; Laura F Michael; Robert Barr; Chahrzad Montrose; Patrick I Eacho; Guoqing Cao; Thomas P Burris
Journal:  J Pharmacol Exp Ther       Date:  2003-07-31       Impact factor: 4.030

7.  Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation.

Authors:  David J Bettoun; Thomas P Burris; Keith A Houck; Donald W Buck; Keith R Stayrook; Berket Khalifa; Jianfen Lu; William W Chin; Sunil Nagpal
Journal:  Mol Endocrinol       Date:  2003-07-31

8.  Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta.

Authors:  Srilatha Raghuram; Keith R Stayrook; Pengxiang Huang; Pamela M Rogers; Amanda K Nosie; Don B McClure; Lorri L Burris; Sepideh Khorasanizadeh; Thomas P Burris; Fraydoon Rastinejad
Journal:  Nat Struct Mol Biol       Date:  2007-11-25       Impact factor: 15.369

9.  Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease.

Authors:  Atul R Chopra; Jean-Francois Louet; Pradip Saha; Jie An; Franco Demayo; Jianming Xu; Brian York; Saul Karpen; Milton Finegold; David Moore; Lawrence Chan; Christopher B Newgard; Bert W O'Malley
Journal:  Science       Date:  2008-11-28       Impact factor: 47.728

10.  T0901317 is a dual LXR/FXR agonist.

Authors:  Keith A Houck; Kristen M Borchert; Christopher D Hepler; Jeffrey S Thomas; Kelli S Bramlett; Laura F Michael; Thomas P Burris
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

View more
  49 in total

1.  DGCR14 induces Il17a gene expression through the RORγ/BAZ1B/RSKS2 complex.

Authors:  Ichiro Takada
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

Review 2.  Circadian molecular clock in lung pathophysiology.

Authors:  Isaac K Sundar; Hongwei Yao; Michael T Sellix; Irfan Rahman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-11       Impact factor: 5.464

3.  Molecular Targets for Small-Molecule Modulators of Circadian Clocks.

Authors:  Baokun He; Zheng Chen
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

4.  Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors α and γ.

Authors:  Hiroyuki Kojima; Ryuta Muromoto; Miki Takahashi; Shinji Takeuchi; Yukimasa Takeda; Anton M Jetten; Tadashi Matsuda
Journal:  Toxicol Appl Pharmacol       Date:  2012-01-24       Impact factor: 4.219

5.  Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.

Authors:  Naresh Kumar; Douglas J Kojetin; Laura A Solt; K Ganesh Kumar; Philippe Nuhant; Derek R Duckett; Michael D Cameron; Andrew A Butler; William R Roush; Patrick R Griffin; Thomas P Burris
Journal:  ACS Chem Biol       Date:  2010-12-06       Impact factor: 5.100

6.  Antiobesity Effect of a Small Molecule Repressor of RORγ.

Authors:  Mi Ra Chang; Yuanjun He; Tanya M Khan; Dana S Kuruvilla; Ruben Garcia-Ordonez; Cesar A Corzo; Thaddeus J Unger; David W White; Susan Khan; Li Lin; Michael D Cameron; Theodore M Kamenecka; Patrick R Griffin
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

7.  Small molecule amides as potent ROR-γ selective modulators.

Authors:  Pasha M Khan; Bahaa El-Dien M El-Gendy; Naresh Kumar; Ruben Garcia-Ordonez; Li Lin; Claudia H Ruiz; Michael D Cameron; Patrick R Griffin; Theodore M Kamenecka
Journal:  Bioorg Med Chem Lett       Date:  2012-11-22       Impact factor: 2.823

Review 8.  Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases.

Authors:  Gabriele Sulli; Emily N C Manoogian; Pam R Taub; Satchidananda Panda
Journal:  Trends Pharmacol Sci       Date:  2018-07-27       Impact factor: 14.819

Review 9.  The mammalian clock and chronopharmacology.

Authors:  Kristine Griffett; Thomas P Burris
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

Review 10.  REV-ERB and ROR nuclear receptors as drug targets.

Authors:  Douglas J Kojetin; Thomas P Burris
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.